Confirmation of the Cardiac Safety of PGF(2α) Receptor Antagonist OBE022 in a First‐in‐Human Study in Healthy Subjects, Using Intensive ECG Assessments

OBE022, a new orally active prostaglandin F(2α) receptor antagonist (OBE022) with myometrial selectivity is being developed to reduce uterine contractions during preterm labor. This first‐in‐human study evaluated the effect of OBE022 following multiple doses on the QT interval in 23 healthy postmeno...

Descripción completa

Detalles Bibliográficos
Autores principales: Täubel, Jörg, Lorch, Ulrike, Coates, Simon, Fernandes, Sara, Foley, Paul, Ferber, Georg, Gotteland, Jean‐Pierre, Pohl, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221050/
https://www.ncbi.nlm.nih.gov/pubmed/29489066
http://dx.doi.org/10.1002/cpdd.447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221050/
https://www.ncbi.nlm.nih.gov/pubmed/29489066
http://dx.doi.org/10.1002/cpdd.447

Ejemplares similares